NKTX NASDAQ
Nkarta, Inc.
1W: -12.1%
1M: -18.7%
3M: -22.6%
YTD: +12.4%
1Y: +24.9%
3Y: -52.0%
5Y: -91.0%
$2.22
-0.04 (-1.77%)
Weekly Expected Move ±12.5%
$2
$2
$2
$3
$3
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$158.8M
52W Range1.7-3.72
Volume591,793
Avg Volume716,698
Beta0.92
Dividend—
Analyst Ratings
Company Info
CEOPaul J. Hastings
Employees108
SectorHealthcare
IndustryBiotechnology
IPO Date2020-07-10
Websitenkartatx.com
1150 Veterans Boulevard
South San Francisco, CA 94080
US
South San Francisco, CA 94080
US
415 582 4923
About Nkarta, Inc.
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Latest News
Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
NKTX Nkarta, Inc. - Conviction Play for Autoimmune Treatment
Nkarta (NASDAQ:NKTX) Stock Price Down 3.1% – Here’s Why
NKTX Stock Up on Upbeat Regulatory Update on Lead Autoimmune Program
Nkarta rises on FDA agreement for amended trial protocol
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| HASTINGS PAUL J | S-Sale | 1,776 | $2.71 | 2026-06-18 |
| Vratsanos George | A-Award | 37,000 | $2.46 | 2026-06-10 |
| Scheiner Zachary | A-Award | 37,000 | $2.46 | 2026-06-10 |
| PATTERSON LEONE D | A-Award | 37,000 | $2.46 | 2026-06-10 |
| Dybbs Michael | A-Award | 37,000 | $2.46 | 2026-06-10 |